UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

European journal of cancer (1990), 2018-05, Vol.94, p.115-125

2018

Volltextzugriff (PDF)

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

Journal of clinical oncology, 2017-09, Vol.35 (27), p.3097-3104

2017

Volltextzugriff (PDF)

Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2014-03, Vol.32 (7), p.671-677

2014

Volltextzugriff (PDF)

Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3402-3407

2012

Volltextzugriff (PDF)

Textbook of Clinical Trials in Oncology: A Statistical Perspective

1, 2019

Volltextzugriff (PDF)

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

Journal of clinical oncology, 2012-05, Vol.30 (13), p.1534-1540

2012

Volltextzugriff (PDF)

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

Journal of clinical oncology, 2010-05, Vol.28 (13), p.2137-2143

2010

Volltextzugriff (PDF)

Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes

Journal of surgical oncology, 2017-12, Vol.116 (8), p.969-982

2017

Volltextzugriff (PDF)

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update

Journal of clinical oncology, 2018-03, Vol.36 (8), p.812-818

2018

Volltextzugriff (PDF)

American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine

CA: a cancer journal for clinicians, 2016-09, Vol.66 (5), p.370-374

2016

Volltextzugriff (PDF)

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5422-5428

2008

Volltextzugriff (PDF)

Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

The Journal of urology, 2021-08, Vol.206 (2), p.298-307

2021

Volltextzugriff (PDF)

Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials

JNCI : Journal of the National Cancer Institute, 2009-02, Vol.101 (4), p.256-266

2009

Volltextzugriff (PDF)

Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy

Journal of clinical oncology, 2013-11, Vol.31 (31), p.3944-3950

2013

Volltextzugriff (PDF)

American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma

Journal of clinical oncology, 2007-06, Vol.25 (17), p.2464-2472

2007

Volltextzugriff (PDF)

Circulating Levels of Inflammatory Cytokines and Risk of Colorectal Adenomas

Cancer research (Chicago, Ill.), 2008, Vol.68 (1), p.323-328

2008

Volltextzugriff (PDF)

Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)

BMC genomics, 2024-05, Vol.25 (1), p.473-10, Article 473

2024

Volltextzugriff (PDF)

Design Issues in Randomized Phase II/III Trials

Journal of clinical oncology, 2012-02, Vol.30 (6), p.667-671

2012

Volltextzugriff (PDF)

Independent data monitoring committees: An update and overview

Urologic oncology, 2015-03, Vol.33 (3), p.143-148

2015

Volltextzugriff (PDF)

Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study

JCO precision oncology, 2018 (2), p.1-14

2018

Volltextzugriff (PDF)

Comparison of regression imputation methods of baseline covariates that predict survival outcomes

Journal of clinical and translational science, 2021-01, Vol.5 (1), p.e40-e40, Article e40

2021

Volltextzugriff (PDF)

Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)

Journal of clinical oncology, 2004-03, Vol.22 (6), p.1025-1033

2004

Volltextzugriff (PDF)

1 – 25 von 469

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(423)
Mit Volltextzugriff
(407)

Publikationsform

Sprache

Englisch
(469)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

Science & Technology
(242)
Life Sciences & Biomedicine
(233)
Humans
(216)
Oncology
(164)
Male
(146)
Middle Aged
(105)
Aged
(104)
Biological And Medical Sciences
(81)
Medical Sciences
(81)
Female
(78)
Adult
(52)
Tumors
(52)
Prostatic Neoplasms - Drug Therapy
(45)
Prognosis
(39)
Prostate Cancer
(38)
Prostatic Neoplasms - Pathology
(38)
Nephrology. Urinary Tract Diseases
(37)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(36)
Risk Factors
(35)
Tumors Of The Urinary System
(34)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin

Textbook of Clinical Trials in Oncology: A Statistical Perspective

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update

American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials

Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy

American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma

Circulating Levels of Inflammatory Cytokines and Risk of Colorectal Adenomas

Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)

Design Issues in Randomized Phase II/III Trials

Independent data monitoring committees: An update and overview

Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study

Comparison of regression imputation methods of baseline covariates that predict survival outcomes

Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)

Suchergebnisse filtern